期刊文献+

Safety and efficacy of Kaffes intraductal self-expanding metal stents in the management of post-liver transplant anastomotic strictures

下载PDF
导出
摘要 BACKGROUND Endoscopic management is the first-line therapy for post-liver-transplant anas-tomotic strictures.Although the optimal duration of treatment with plastic stents has been reported to be 8-12 months,data on safety and duration for metal stents in this setting is scarce.Due to limited access to endoscopic retrograde cholan-giopancreatography(ERCP)during the coronavirus disease 2019 pandemic in our centre,there was a change in practice towards increased usage and length-of-stay of the Kaffes biliary intraductal self-expanding stent in patients with suitable anatomy.This was mainly due to the theoretical benefit of Kaffes stents allowing for longer indwelling periods compared to the traditional plastic stents.METHODS Adult liver transplant recipients aged 18 years and above who underwent ERCP were retrospectively identified during a 10-year period through a database query.Unplanned admissions post-Kaffes stent insertion were identified manually through electronic and scanned medical records.The main outcome was the incidence of complications when stents were left indwelling for 3 months vs 6 months.Stent efficacy was calculated via rates of stricture recurrence between patients that had stenting courses for≤120 d or>120 d.RESULTS During the study period,a total of 66 ERCPs with Kaffes insertion were performed in 54 patients throughout their stenting course.In 33 ERCPs,the stent was removed or exchanged on a 3-month interval.No pancreatitis,perfor-ations or deaths occurred.Minor post-ERCP complications were similar between the 3-month(abdominal pain and intraductal migration)and 6-month(abdominal pain,septic shower and embedded stent)groups-6.1%vs 9.1%respectively,P=0.40.All strictures resolved at the end of the stenting course,but the stenting course was variable from 3 to 22 months.The recurrence rate for stenting courses lasting for up to 120 d was 71.4%and 21.4%for stenting courses of 121 d or over(P=0.03).There were 28 patients that were treated with a single ERCP with Kaffes,21 with removal after 120 d and 7 within 120 d.There was a significant improvement in stricture recurrence when the Kaffes was removed after 120 d when a single ERCP was used for the entire stenting course(71.0%vs 10.0%,P=0.01).CONCLUSION Utilising a single Kaffes intraductal fully-covered metal stent for at least 4 months is safe and efficacious for the management of post-transplant anastomotic strictures.
出处 《World Journal of Transplantation》 2024年第2期88-98,共11页 世界移植杂志
  • 相关文献

参考文献2

二级参考文献88

  • 1[1]Martin RF,Rossi RL.Bile duct injuries.Spectrum,mechanisms of injury,and their prevention.Surg Clin North Am 1994; 74:781-803; discussion 805-807
  • 2[2]Porayko MK,Kondo M,Steers JL.Liver transplantation:late complications of the biliary tract and their management.Semin Liver Dis 1995; 15:139-155
  • 3[3]Vitale GC,Reed DN Jr,Nguyen CT,Lawhon JC,Larson GM.Endoscopic treatment of distal bile duct stricture from chronic pancreatitis.Surg Endosc 2000; 14:227-231
  • 4[4]Bismuth H.Postoperative strictures of the bile duct.In:Blumgart LH,ed.The Biliary Tract.Edinburgh:Churchill Livingstone,1982:209-218
  • 5[5]Warshaw AL,Schapiro RH,Ferrucci JT Jr,Galdabini JJ.Persistent obstructive jaundice,cholangitis,and biliary cirrhosis due to common bile duct stenosis in chronic pancreatitis.Gastroenterology 1976; 70:562-567
  • 6[6]Bergman JJ,van den Brink GR,Rauws EA,de Wit L,Obertop H,Huibregtse K,Tytgat GN,Gouma DJ.Treatment of bile duct lesions after laparoscopic cholecystectomy.Gut 1996; 38:141-147
  • 7[7]Davidson BR,Rai R,Nandy A,Doctor N,Burroughs A,Rolles K.Results of choledochojejunostomy in the treatment of biliary complications after liver transplantation in the era of nonsurgical therapies.Liver Transpl 2000; 6:201-206
  • 8[8]Al-Mofleh IA,Aljebreen AM,AI-Amri SM,Al-Rashed RS,Al-Faleh FZ,Al-Freihi HM,Abdo AA,Isnani AC.Biochemical and radiological predictors of malignant biliary strictures.World J Gastroenterol 2004; 10:1504-1507
  • 9[9]Patel AH,Harnois DM,Klee GG,LaRusso NF,Gores GJ.The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.Am J Gastroenterol 2000; 95:204-207
  • 10[10]Mann DV,Edwards R,Ho S,Lau WY,Glazer G.Elevated tumour marker CA19-9:clinical interpretation and influence of obstructive jaundice.Eur J Surg Oncol 2000; 26:474-479

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部